ライフサイエンスコーパス: biopsy-proven

1 loped transformed lymphoma, of which 51 were biopsy proven.

2 ve disease that was clinically diagnosed and biopsy proven) (19.2% vs. 4.4%, P=0.003).

3 The outcomes of 20 patients with FMF and biopsy-proven AA amyloidosis that were transplanted betw

4 on systems were applied to 502 patients with biopsy-proven AAV: 1) the Chapel Hill Consensus Conferen

5 ut indication), as well as 3,843 men who had biopsy-proven absence of prostate cancer at the trial en

6 xic memory cells (TcMs) associated best with biopsy-proven ACR with a sensitivity/specificity of 88%

7 From 1981 to 2009, 82 patients with biopsy-proven active myocarditis were consecutively enro

8 evolution of a large sample of patients with biopsy-proven active myocarditis, looking for accessible

9 Incidence of biopsy proven acute rejection was 18.5%.

10 ed treatment of 13 consecutive patients with biopsy-proven acute AMR with intravenous cyclophosphamid

11 were those children (n=35), who experienced biopsy-proven acute cellular rejection (ACR) within 60 d

12 Biopsy-proven acute cellular rejection was noted in 5 re

13 Biopsy-proven acute cellular rejection was present in 15

14 ectors were defined as those who experienced biopsy-proven acute cellular rejection within 60 days of

15 were those children (n=16), who experienced biopsy-proven acute cellular rejection within 60 days of

16 Compared to MMF, rates of freedom from first biopsy-proven acute kidney or pancreas rejection were su

17 Rates of biopsy-proven acute rejection (5.7% vs 7.9%), adverse ev

18 Less biopsy-proven acute rejection (AR) (p = 0.005), cytomega

19 The primary outcome was the incidence of biopsy-proven acute rejection (BPAR) (Banff grade >/=1),

20 oportion of patients who experienced treated biopsy-proven acute rejection (BPAR) during the first ye

21 lar between alemtuzumab and rATG groups, but biopsy-proven acute rejection (BPAR) episodes occurred i

22 Cumulative rates of biopsy-proven acute rejection (BPAR) from first randomiz

23 us trough concentration and the incidence of biopsy-proven acute rejection (BPAR) in 216 moderately s

24 dose [mg]/trough concentration [mug/L]) and biopsy-proven acute rejection (BPAR) the first 90 days p

25 The 1-year incidence of biopsy-proven acute rejection (BPAR) was 14.1% in Africa

26 Primary endpoints were: incidence of biopsy-proven acute rejection (BPAR) with a serum creati

27 eviously showed at 1 year posttransplant low biopsy-proven acute rejection (BPAR), acceptably high re

28 irst week), slow graft function (SGF), first biopsy-proven acute rejection (BPAR), and graft failure,

29 ry outcomes were the number of patients with biopsy-proven acute rejection (BPAR), estimated glomerul

30 Breakthrough CMV, resistant CMV, biopsy-proven acute rejection (BPAR), graft loss, opport

31 t failure, and death with functioning graft, biopsy-proven acute rejection (BPAR), new-onset diabetes

32 ate whether the concentration of Evl affects biopsy-proven acute rejection (BPAR), renal function, ad

33 tcomes, including delayed graft function and biopsy-proven acute rejection (BPAR).

34 the impact of PPI use on the 1-year rates of biopsy-proven acute rejection (BPAR).

35 Primary endpoint was the incidence of biopsy-proven acute rejection (BPAR).

36 examine the impact of dose manipulations on biopsy-proven acute rejection (BPAR).

37 ies of patients treated with alemtuzumab for biopsy-proven acute rejection (BPAR).

38 Biopsy-proven acute rejection (odds ratio [OR] 2.32, 95%

39 prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR) during TAC withdra

40 There were no significant differences in biopsy-proven acute rejection (two trials, n=1093; risk

41 failures (death, graft failure, locally read biopsy-proven acute rejection [BPAR], or loss to follow-

42 Biopsy-proven acute rejection and acute rejection were s

43 Endpoints included development of biopsy-proven acute rejection and analysis of graft surv

44 Endpoints included development of biopsy-proven acute rejection and analysis of graft surv

45 eatment efficacy defined as the incidence of biopsy-proven acute rejection and estimated creatinine c

46 The incidence of biopsy-proven acute rejection at 2 years was higher in t

47 There were no differences in the rates of biopsy-proven acute rejection at 3 years after transplan

48 TG showed a significantly lower incidence of biopsy-proven acute rejection at last follow-up 11% (32/

49 The rate of biopsy-proven acute rejection by 12 months was lower in

50 Biopsy-proven acute rejection episodes occurred in three

51 e of composite efficacy failure (graft loss, biopsy-proven acute rejection or severe graft dysfunctio

52 ears after transplantation, the incidence of biopsy-proven acute rejection was low and similar (Tac/B

53 The 1-year incidence of biopsy-proven acute rejection was monitored.

54 A lower incidence of biopsy-proven acute rejection was seen in patients recei

55 oint was the 12-month composite incidence of biopsy-proven acute rejection, acute rejection associate

56 n patterns were compared among patients with biopsy-proven acute rejection, borderline changes, and i

57 fficacy endpoint and its components (treated biopsy-proven acute rejection, graft loss, death, or los

58 no difference in renal function or rates of biopsy-proven acute rejection, graft loss, opportunistic

59 The composite efficacy endpoint of treated biopsy-proven acute rejection, graft loss, or death was

60 cacy failure endpoint was graft loss, death, biopsy-proven acute rejection, or lost to follow-up.

61 Incidence of biopsy-proven acute rejection, patient and graft surviva

62 Two years after transplantation, the biopsy-proven acute rejection-free survival was worse in

63 raft function, and incidence and severity of biopsy-proven acute rejection.

64 Patient survival and biopsy-proven acute rejections were statistically simila

65 ents with follicular lymphoma and subsequent biopsy-proven aggressive histology transformation.

66 One hundred forty-two patients with biopsy-proven AH that survived the first episode were in

67 studied a cohort including 162 patients with biopsy-proven AH.

68 Furthermore, in a cohort of patients with biopsy-proven AKI (n = 53), Fg immunoreactivity in the t

69 Two hundred six consecutive patients with biopsy-proven AL amyloidosis were investigated in this p

70 70 years who were heavy drinkers with severe biopsy-proven alcoholic hepatitis, as indicated by recen

71 Biopsy-proven allograft rejection rate increased after m

72 Biopsy-proven AMR occurred in 7 (70%) of the 10 patients

73 ed trial, we randomly assigned patients with biopsy-proven AMR to receive rituximab (375 mg/m) or pla

74 ents in four pediatric heart recipients with biopsy-proven AMR, hemodynamic compromise, positive cros

75 e proven localised amyloidosis classified as biopsy proven amyloid deposition confined to one site or

76 tive sera from 34 kidney recipients, 19 with biopsy-proven antibody-mediated rejection (AMR) + and 15

77 t/graft survival and cumulative incidence of biopsy proven AR.

78 47 patients of the 185 patients included, a biopsy-proven AR occurred.

79 and a comparator cohort of 25 patients with biopsy-proven ATTR V122I amyloidosis recruited from Sept

80 In this series of patients with biopsy-proven ATTRwt, poor functional capacity and atria

81 patients who present with palpable or needle biopsy-proven axillary metastases, patients with positiv

82 WA women aged between 40 and 70 years with a biopsy-proven BBD diagnosis.

83 nd innumerable cutaneous BCCs presented with biopsy-proven BCC in his lungs.

84 n field 10 months after undergoing ESB for a biopsy-proven BCC.

85 6 cases of biopsy-proven cancer, 35 cases of biopsy-proven benign lesions, and 52 normal or benign ca

86 zed for 51 cancer cases and 51 controls with biopsy-proven benign lesions, matched by age and year-of

87 There was a trend toward higher incidence of biopsy-proven BKV nephropathy in Group 1 (4.7% vs. 0.8%,

88 blood DC (PBDC) deficiency in patients with biopsy-proven BKVN, raising the possibility that reducti

89 We analyzed 40 patients with biopsy-proven BPH who underwent a second prostate biopsy

90 development of advanced disease, defined as biopsy-proven bridging fibrosis or cirrhosis.

91 Fifty adult patients with MIg and biopsy-proven C3G were extracted from the French nationa

92 which 40 were patients with newly diagnosed, biopsy-proven CA (65.5+/-10.8 years, 65% male, 62.5% amy

93 that allows for three-dimensional mapping of biopsy-proven cancer lesions as well as potential future

94 The cohort included 36 cases of biopsy-proven cancer, 35 cases of biopsy-proven benign l

95 ave undergone active surveillance (including biopsy-proven cancers) and a better understanding of how

96 domized clinical trial open to patients with biopsy-proven carcinoma of the esophagus.

97 utcome of IPH by retrospectively studying 69 biopsy-proven cases of IPH.

98 Included in this study are autopsy/cerebral biopsy-proven cases of vCJD referred to the National CJD

99 Given the limited number of biopsy-proven cases with ethnically matched controls, we

100 TTG and/or EMA, however only 12 children had biopsy proven CD (11.3%).

101 hy relatives of 70 Romanian index cases with biopsy-proven CD (87% of all first-degree family members

102 oma or anaplastic large-T-cell lymphoma, had biopsy-proven CD30-positive tumours, had an Eastern Coop

103 Forty-one children with biopsy-proven celiac disease (median age, 9 years old; 1

104 ed at examining the annual incidence rate of biopsy-proven celiac disease among children in Sweden ov

105 ro-conversion was 8/205 and the incidence of biopsy-proven celiac disease cases was 5/205.

106 ssessed medical records of 840 patients with biopsy-proven celiac disease for diagnoses of NIDDM, hyp

107 a total of 634 first degree relatives of 186 biopsy-proven celiac disease patients diagnosed between

108 530 children with biopsy-proven celiac disease were included.

109 Then, in the intervention study, adults with biopsy-proven celiac disease were randomly assigned to g

110 All (4 of 4) DSCI patients had biopsy-proven chronic allograft injury and/or recurrence

111 groups (8/43, 14/43, and 12/42, P=0.34), but biopsy-proven chronic allograft injury incidence was sig

112 olic cirrhosis and, 6 years later, developed biopsy-proven chronic HEV infection.

113 Biopsy-proven chronic orbital inflammation was present i

114 d in this meta-analysis, among whom 4725 had biopsy-proven cirrhosis (prevalence rate, 24%; 95% CI, 2

115 All patients had HCV infection and biopsy-proven cirrhosis, were Child-Pugh class A, and ha

116 Twelve patients (18.75%) showed biopsy-proven cirrhosis.

117 against 21 board-certified dermatologists on biopsy-proven clinical images with two critical binary c

118 an age = 44 +/- 13 years (range 19-64)) with biopsy proven coeliac disease referred for neurological

119 Eight hundred twenty-two patients with biopsy-proven colorectal cancer, who underwent (18)F-FDG

120 s (mean age: 54.3+/-11 years; 55% male) with biopsy-proven COP in a tertiary lung center between 2009

121 17, 20, 24, 36, and 38 association with skin biopsy proven cSCC.

122 Four patients with biopsy-proven cutaneous calciphylaxis were treated with

123 ty dermoscopic images of 20 outpatients with biopsy-proven cutaneous metastases and known diagnosis o

124 With median follow-up of 95 months, biopsy-proven cute rejection incidence was similar in th

125 unted in 40 urine samples from patients with biopsy-proven definitive PVN.

126 Five pregnant patients with a biopsy-proven diagnosis of malignancy who underwent (18)

127 ed, and no deaths from melanoma arising from biopsy-proven DN occurred through the latest dermatology

128 poietic cell transplantation recipients with biopsy-proven EBV-lymphoproliferative disease (EBV-LPD).

129 January 1, 2014, and December 31, 2016, with biopsy-proven EMPD in whom HRCM was used to monitor trea

130 Of the 17 biopsy-proven episodes, 12 were antibody-mediated reject

131 hods Fifty-three consecutive patients with a biopsy-proven extracardiac diagnosis of systemic sarcoid

132 ODS AND Eighty-one consecutive patients with biopsy-proven extracardiac sarcoidosis were prospectivel

133 Sixteen patients of biopsy-proven eyelid malignancy (7 squamous cell carcino

134 267 consecutive patients with biopsy proven fatty liver or non-alcoholic steatohepatit

135 rd-approved database was queried to identify biopsy-proven first AR episodes occurring from January 2

136 ed YAP protein in glomeruli of patients with biopsy-proven focal segmental glomerulosclerosis (FSGS).

137 In all, 174 consecutive biopsy-proven G1 CHC patients were evaluated by anthropo

138 3 of 25 temporal arteries from patients with biopsy-proven GCA.

139 Eighteen patients with biopsy-proven GEP-NETs were evaluated with (68)Ga-DOTANO

140 increased 79-fold (P<0.001) in patients with biopsy-proven glomerular disease and a 50% decrease in k

141 Parallel human studies showed that biopsy-proven glomerular injury associated with increase

142 of all organs were at an increased risk for biopsy-proven graft rejection within 4 weeks after detec

143 We correlated CMV infection, biopsy-proven graft rejection, and graft loss in 1,414 p

144 ging Reporting and Data System category 5 or biopsy-proven HCC and who were undergoing TAE were enrol

145 the dermatology department for a subsequent biopsy-proven head and neck malignancy through April 201

146 Of these 5 patients, 2 had biopsy-proven HER2-positive metastases and went on to be

147 Patients with biopsy-proven high-grade dysplasia or esophageal cancer

148 We identified 6 patients with biopsy-proven high-risk prostate cancer who were referre

149 Superimposition of biopsy-proven histologic data can allow creation of a mo

150 , or 5 masses assessed at diagnostic US with biopsy-proven histologic findings and BI-RADS 3 masses s

151 A prospective cohort of 84 patients with biopsy-proven HIV+MCD were treated with risk-stratified

152 rinary NGAL was much higher in patients with biopsy-proven HIVAN than in HIV-positive and HIV-negativ

153 The study included 214 biopsy-proven HNSCC patients who underwent a posttherapy

154 The study included 134 biopsy-proven HNSCC patients with 227 follow-up PET/CT s

155 erials and Methods Consecutive patients with biopsy-proven HRLs who underwent surgery or at least 2 y

156 We recruited patients (18-75 years) with biopsy-proven idiopathic membranous nephropathy, a plasm

157 e of remission duration in 376 patients with biopsy-proven idiopathic/primary MGN who achieved a remi

158 low-up, we randomized 34 adult patients with biopsy-proven IgA nephropathy and proteinuria >1 g/d, ma

159 Here, we studied 141 Caucasian patients with biopsy-proven IgA nephropathy who had minor abnormalitie

160 ohort study included 639 white patients with biopsy-proven IgAN since 1979 (mean age at diagnosis, 40

161 Only cases with biopsy-proven IgG4-RHP were considered and included in t

162 PLA2R1 in a cohort of 95 white patients with biopsy-proven iMN and assessed all 30 exons of PLA2R1, i

163 R1) allele associate most significantly with biopsy-proven iMN, suggesting that rare genetic variants

164 on viral infection of renal allografts, with biopsy-proven incidence of approximately 5%.

165 All 7 patients had locally advanced, biopsy-proven, infiltrative BCC that was not amenable to

166 tions in an independent set of patients with biopsy-proven inflammation/BPH (n = 61) and prostate can

167 uctal carcinoma in situ (DCIS) components of biopsy-proven invasive breast cancer before surgery and

168 enter study of 593 consecutive patients with biopsy-proven invasive breast cancer who underwent breas

169 The data set of biopsy-proven invasive breast cancers included 74 (88%)

170 cohort of 1426 patients diagnosed as having biopsy-proven KC from January 1, 1999, through December

171 in the folic acid model and in patients with biopsy-proven kidney fibrosis.

172 e masked review of images from patients with biopsy-proven lacrimal gland pathology.

173 Fifty-three patients with biopsy-proven LCDD were prospectively followed at the UK

174 We report 23 patients with biopsy-proven LCH associated with Erdheim-Chester diseas

175 ountries evaluated an RCM study set from 100 biopsy-proven lesions, including 55 melanocytic nevi, 20

176 ive study included consecutive patients with biopsy-proven LM and LMM located on the head and neck ar

177 We identified 606 patients with biopsy proven localised amyloidosis (likely light-chain

178 red ten men and 25 external controls who had biopsy-proven low-risk prostate cancer and had chosen to

179 This was a retrospective study of 261 biopsy-proven lung cancer patients at a single tertiary

180 A total of 1,171 patients with biopsy-proven lung cancer who had undergone (18)F-FDG PE

181 A total of 201 patients with biopsy-proven lung cancer, who underwent therapy assessm

182 munologic criterion OR the patient must have biopsy-proven lupus nephritis in the presence of antinuc

183 We present a case of biopsy-proven lymphocytic vasculitis mimicking a brain t

184 Patients with biopsy-proven lymphoma, breast cancer, or head and neck

185 Newly diagnosed, biopsy-proven malignancies were detected in 8.1% (56 of

186 presentation and outcome of 80 patients with biopsy-proven MCGN, which were identified in the retrosp

187 with findings consistent with metastasis had biopsy-proven metastasis.

188 Ten patients with biopsy-proven metastatic cancer were included.

189 on episodes: clinically suspected (n=19) and biopsy-proven mild (n=4), moderate (n=2), and severe (n=

190 ropriate management of incompletely excised, biopsy-proven, mild and moderate dysplastic nevi (DN).

191 ed clinical trial involving 98 patients with biopsy-proven myeloma cast nephropathy requiring hemodia

192 nal recovery, we identified 39 patients with biopsy-proven myeloma kidney, the majority of whom had s

193 e (1) characterized the plasma BA profile in biopsy-proven NAFL and NASH and compared to controls and

194 - 1Beta) in obese subjects (BMI >/= 35) with biopsy proven NAFLD.

195 lyzed serum metabolomes of 535 patients with biopsy-proven NAFLD (353 with simple steatosis and 182 w

196 iopsies and clinical data from patients with biopsy-proven NAFLD (56 in the discovery cohort and 34 i

197 Sixty-five consecutive children with biopsy-proven NAFLD (age, mean +/- SD, 11.7 +/- 2.1 yr;

198 ifying differences in IM between adults with biopsy-proven NAFLD (simple steatosis [SS] or nonalcohol

199 patients with NAFLD (age, >/= 18 years) with biopsy-proven NAFLD and an SF measurement within 6 month

200 We sought to determine whether subjects with biopsy-proven NAFLD and evidence of an inadequate intake

201 Overweight children with biopsy-proven NAFLD and overweight children without NAFL

202 was conducted in 83 unselected patients with biopsy-proven NAFLD from a single center.

203 Forty nonobese, nondiabetic, normolipidemic biopsy-proven NAFLD patients (20 with SS and 20 with NAS

204 In biopsy-proven NAFLD patients, SREBF-2 predicted nonalcoh

205 In biopsy-proven NAFLD patients, the SREBF-1c A allele conf

206 r study of children with well-characterized, biopsy-proven NAFLD to (1) assess the presence and signi

207 ta from 229 well-characterized patients with biopsy-proven NAFLD were collected.

208 Children with biopsy-proven NAFLD were eligible for inclusion.

209 Fifty-seven patients with biopsy-proven NAFLD were enrolled.

210 In all, 172 patients from two centers with biopsy-proven NAFLD were included in this study.

211 Fifty patients with biopsy-proven NAFLD who participated in a randomized tri

212 ng 117 consecutive patients (56% women) with biopsy-proven NAFLD who underwent a standardized researc

213 Among children with biopsy-proven NAFLD, 26 had definite nonalcoholic steato

214 a large, diverse population of patients with biopsy-proven NAFLD, supporting the potential usefulness

215 a well-characterized cohort of patients with biopsy-proven NAFLD, this study demonstrates that hepati

216 3 or 4) in well-characterized patients with biopsy-proven NAFLD.

217 istology and glucose and lipid metabolism in biopsy-proven NAFLD.

218 sease activity and severity in patients with biopsy-proven NAFLD.

219 gy and lipoprotein and glucose metabolism in biopsy-proven NAFLD.

220 n a well-characterized cohort of adults with biopsy-proven NAFLD.

221 fibrosis in well-characterized patients with biopsy-proven NAFLD.

222 study we examined 65 patients with advanced biopsy-proven NASH (fibrosis stage 3-4) and 54 with mild

223 after USPIO administration in patients with biopsy-proven NASH (n = 13), hepatic steatosis without N

224 E in a cohort of patients aged 50 years with biopsy-proven NASH and fibrosis level 3 or greater.

225 undred and nine morbidly obese patients with biopsy-proven NASH underwent bariatric surgery at the Un

226 A total of 137 subjects with biopsy-proven NASH were enrolled and randomly assigned t

227 (body mass index [BMI], 25-40 kg/m(2)) with biopsy-proven NASH were randomized in a 2:1 ratio to rec

228 , placebo-controlled trial, 50 patients with biopsy-proven NASH were randomized to either ezetimibe 1

229 ase 2, double-blind study, 124 subjects with biopsy-proven NASH were randomized to once-daily placebo

230 Fifty patients with biopsy-proven NASH were randomly assigned to either cole

231 ients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general popul

232 ed placebo-control study of 55 patients with biopsy-proven NASH who received either oral betaine (20

233 36 with simple steatosis [SS], and 122 with biopsy-proven NASH).

234 We recruited 152 patients with biopsy-proven NASH, 63% of whom were Hispanic and 37% of

235 ed trials (RCTs) including 964 patients with biopsy-proven NASH, comparing vitamin E, thiazolidinedio

236 I-PDFF) and liver histology in patients with biopsy-proven NASH.

237 sferase and liver histology in patients with biopsy-proven NASH.

238 examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no).

239 were evaluated in the dermatology clinic for biopsy-proven NMSC of the head and neck during the study

240 Clip placement in the biopsy-proven node at diagnosis and evaluation of resect

241 In biopsy-proven node-positive breast cancer after NAC, a l

242 Downstaging of biopsy-proven node-positive patients with neoadjuvant ch

243 In this study, we examined patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) f

244 Our cohort consisted of 139 patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) f

245 lly, plasma DMGV levels were correlated with biopsy-proven nonalcoholic steatohepatitis (NASH) in a h

246 BAS, to decrease liver fat in patients with biopsy-proven nonalcoholic steatohepatitis (NASH).

247 main 100% specific, with no autopsy/cerebral biopsy-proven noncases classified as probable in life.

248 18 patients with biopsy-proven NSCLC (n = 10) or HNSCC (n = 8) were inclu

249 trospective case-control study was done on 5 biopsy-proven OCP subjects and 6 healthy volunteers.

250 Eligible patients had biopsy-proven oesophageal cancer that was unsuitable for

251 There were 25 episodes of biopsy-proven or clinically presumed rejection in 22 pat

252 re retrospectively analyzed for PTLD, either biopsy-proven or probable disease.

253 A total of 437 patients with biopsy-proven or probable early-stage lung cancer were e

254 reas 11 of 13 patients treated with CTLs for biopsy-proven or probable LPD achieved sustained complet

255 If there are palpable, biopsy-proven, or grossly apparent metastases at the tim

256 th borderline resectable or locally advanced biopsy-proven pancreatic ductal adenocarcinoma, an Easte

257 itis (RAVE) Trial who had renal involvement (biopsy proven pauci-immune GN, red blood cell casts in t

258 Ten patients with biopsy-proven PCa (5 with primary PCa and 5 with prostat

259 Materials and Methods Eighteen patients with biopsy-proven PCa provided informed consent to be includ

260 tudy of patients aged 18 years or older with biopsy-proven peripheral T1-T2N0M0 non-small cell tumors

261 Patients with biopsy-proven PMN and nephrotic syndrome after 6 months

262 ria, 48 (20%) sustained viremia, and 17 (7%) biopsy-proven polyomavirus-associated nephropathy.

263 ded were 63 kidney allograft recipients with biopsy proven primary MN followed up for 77.0 (39-113) m

264 with 1623 women aged 18 years or older with biopsy-proven primary breast cancer who were scheduled f

265 s in two cohorts of children and adults with biopsy-proven primary FSGS: 70 patients from the North A

266 Two patients with biopsy-proven primary refractory HL were treated off-stu

267 Patients with biopsy-proven prostate cancer (n = 10) who underwent pro

268 Twenty-one patients with biopsy-proven prostate cancer underwent (68)Ga-PSMA-HBED

269 In this case series, 3 patients with biopsy-proven recalcitrant HHD were evaluated in the out

270 ained virological response, and may induce a biopsy-proven regression of liver fibrosis in a liver tr

271 ely postoperatively, and a trend toward more biopsy-proven rejection (P = 0.073).

272 howed that the IR of Tc associated best with biopsy-proven rejection (sensitivity >87.5%, specificity

273 te between 6 months and last follow-up), and biopsy-proven rejection after 6 months.

274 amples from 17 ITx recipients, 14% developed biopsy-proven rejection at a median of 25 days post-ITx.

275 , there were no differences in incidences of biopsy-proven rejection episodes.

276 d graft survival, a significant incidence of biopsy-proven rejection occurred in this subset of close

277 d graft survival, a significant incidence of biopsy-proven rejection occurred in this subset of close

278 Biopsy-proven rejection was defined according to the Ban

279 s included patient survival, graft survival, biopsy-proven rejection, and infectious or noninfectious

280 postoperative events, such as renal failure, biopsy-proven rejection, and stroke.

281 he median TAC CV% was 53.4% in patients with biopsy-proven rejection, which was significantly higher

282 nd predicted ACR events up to 40 days before biopsy-proven rejection.

283 Ten of 46 patients had biopsy-proven rejection.

284 he observed significantly lower incidence of biopsy-proven rejection.

285 men; mean age, 71.9 years +/- 10.9) with 217 biopsy-proven renal cell carcinoma tumors treated with t

286 yzed data from 164 consecutive patients with biopsy-proven renal involvement of ANCA-associated vascu

287 rty-four patients with previously untreated, biopsy-proven sarcoma stratified into three age groups (

288 centers and included 123 patients, with 132 biopsy-proven screening-detected cancers, and 52 examina

289 , 18-75 y) with recent onset of jaundice and biopsy-proven severe AH in our study, performed at 18 ho

290 vaccine and then compared with the number of biopsy-proven skin cancers recorded over a similar perio

291 Biopsy-proven skin cancers were recorded for 16 months (

292 d to the British Columbia Cancer Agency with biopsy-proven stage I to III breast cancer (BC), diagnos

293 SA, enrolling patients with newly diagnosed, biopsy-proven stage III or IV squamous-cell carcinoma of

294 A consecutive series of 55 patients with biopsy-proven SUSCC without bone invasion treated by wid

295 Participants included women with biopsy-proven T1-2 breast cancer with clinically negativ

296 rameters were compared between subjects with biopsy-proven vasculitis (CSS; n = 8), >/=4 ACR criteria

297 A total of 222 consecutive patients with biopsy-proven viral myocarditis and CMR were enrolled.

298 en; age, 42 [28-52] years) with a history of biopsy-proven viral myocarditis and drug-refractory VT;

299 tion with a wide range of clinical symptoms, biopsy-proven viral myocarditis is associated with a lon

300 Eligibility criteria were biopsy-proven vulval intraepithelial neoplasia grade 3 a